Clinical trials: Emphysema or COPD
Emphysema or COPD
Zephyr Etude Post-Inscription (French Registry)
The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD) Grade III and Grade IV in order to support…
- Trial name
- NCT04517916
- Testing
- Zephyr Valve
- Where
- 12 sites in France
- Volunteers
- 155 people
- Sponsor
- Pulmonx Corporation
Alpha 1-Antitrypsin Deficiency, Emphysema or COPD
PiMZ Longitudinal Cohort (PiMZ Logic)
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ.
- Trial name
- NCT06505603
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia University
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore…
- Trial name
- NCT03500731
- Testing
- CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Paul Szabolcs
COPD, Chronic Obstructive Pulmonary Disease
Study of COPD Subgroups and Biomarkers
SPIROMICS I, SPIROMICS II, and SPIROMICS III are longitudinal observational studies of Chronic Obstructive Pulmonary Disease (COPD) cohort.
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- SPIROMICS (NCT01969344)
- Where
- 14 sites in United States
- Volunteers
- 2,981 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
COPD, Emphysema
Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD
Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause for morbidity and mortality. Despite the high clinical significance of sarcopenia in COPD, the diagnosis remains elusive because…
- Conditions
- COPD, Emphysema, Sarcopenia
- Trial name
- NCT07059637
- Testing
- Multidisciplinary clinic evaluation, COPD standard of care
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The Cleveland Clinic
COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself.
- Conditions
- COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection, Rhinovirus, Virus Diseases
- Trial name
- NCT06149494
- Testing
- Vapendavir
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Altesa Biosciences, Inc.
Copd, Emphysema
Exploring Novel Biomarkers for Emphysema Detection
The goal of this clinical trial is to evaluate whether voice or capnometry, alone or in combination with other (non invasive) biomarkers can be used to detect emphysema on chest CT-scan in people with chronic obstructive…
- Trial name
- ENBED (NCT05825261)
- Testing
- voice sampling, capnometry
- Where
- 2 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Maastricht University
COPD, Emphysema or COPD
Utilising Hull Lung Health Study Data to Investigate the Performance of TidalSense Diagnostic Algorithms to Identify COPD and Pre-COPD Among Participants in the FRONTIER Programme.
Aim: To investigate the potential for N-Tidal to improve COPD diagnosis and enable detection of pre-COPD*. Objectives: 1. To assess the performance of TidalSense COPD Diagnostic Algorithms for COPD diagnosis in a real-world…
- Conditions
- COPD, Emphysema or COPD, Emphysema
- Trial name
- NCT06788613
- Volunteers
- 1,200 people
- Sponsor
- Chiesi UK
Lung Cancer, Lung Infection
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules.
- Conditions
- Lung Cancer, Lung Infection, COPD, Bronchitis
- Trial name
- NCT06528418
- Testing
- Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- ChromX Health
COPD, Emphysema
Evaluation of Immunological, Microbiological and Metabolomic Profiles in COPD
COPD is a significant health problem worldwide. It affects more than 10% of patients over the age of 40. According to the World Health Organization, it is the third most common cause of death among adults in the world, and the…
- Conditions
- COPD, Emphysema, Chronic Bronchitis, Smoking
- Trial name
- NCT06826560
- Where
- Poland
- Volunteers
- 92 people
- Sponsor
- Medical University of Warsaw
Emphysema or COPD
Post-Market BTVA Registry
Bronchoscopic thermal vapor ablation using Uptake Medical Technology Inc.'s InterVapor System is indicated for treatment of patients with heterogeneous upper lobe emphysema.
- Trial name
- NCT03318406
- Testing
- Bronchoscopic Thermal Vapor Ablation
- Where
- 20 sites in Austria, Germany and 1 more
- Volunteers
- 300 people
- Sponsor
- Uptake Medical Technology, Inc.
Emphysema or COPD, Emphysema
The REDUCE EU Study - Endobronchial Thermal Liquid Ablation (ETLA) for the Treatment of Emphysema
The goal of this clinical trial is to learn if bronchoscopic lung volume reduction with endobronchial thermal liquid ablation (ETLA) works to treat severe emphysema in terms of feasibility and safety.
- Conditions
- Emphysema or COPD, Emphysema, Emphysema, Pulmonary, COPD
- Trial name
- NCT06655428
- Testing
- Endobronchial Therman Liquid Ablation (ETLA)
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Morair Medtech, LLC
Coronary Disease, Emphysema or COPD
Maximizing Benefit of Lung Cancer Screening Incidental Findings of Cardiovascular, Respiratory and Breast Measures
The investigators will implement a patient-centered outcomes tool for participants in lung cancer screening programs that receive clinically important incidental findings relevant to heart, breast and lung health.
- Conditions
- Coronary Disease, Emphysema or COPD, Breast Density
- Trial name
- NCT05900544
- Testing
- System implementation of patient-centered incidental findings report
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Montana
Lung Cancer, COPD
DEPRECAP: Lung Cancer Screening Programme by LDCT for Patients With COPD or Emphysema.
The DEPRECAP (Early detection of lung cancer) study is an ongoing, prospective, longitudinal, multicenter lung cancer screening program that recruited individuals with COPD or emphysema from the pulmonary clinics of Fundación…
- Conditions
- Lung Cancer, COPD, Emphysema
- Trial name
- DEPRECAP (NCT06690385)
- Where
- 2 sites in Spain
- Volunteers
- 1,998 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Emphysema, COPD
Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)
This is a prospective, open-label, multi-center, single-arm study to be conducted at up to 20 investigational sites. The Study plans to enroll up to 140 subjects with severe emphysema and collateral ventilation in the target…
- Conditions
- Emphysema, COPD, Severe Emphysema
- Trial name
- CONVERT (NCT04559464)
- Testing
- AeriSeal, Zephyr Valves
- Where
- 14 sites in Australia, France and 5 more
- Volunteers
- 102 people
- Sponsor
- Pulmonx Corporation
COPD, COPD Exacerbation
Healthy At Home Pilot
The objective is to conduct a pilot-feasibility trial of the "Healthy at Home" program, a multimodal intervention aimed at preventing acute care needs among COPD patients.
- Conditions
- COPD, COPD Exacerbation, Emphysema or COPD
- Trial name
- NCT06000696
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Massachusetts, Worcester
Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
This is a Phase 2, multicenter, double-blind, randomized (1:1), placebo-controlled, 12-week, proof-of-concept study to evaluate the safety and tolerability as well as the mechanistic effect of oral administration of alvelestat…
- Conditions
- Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations, Emphysema or COPD
- Trial name
- ATALANTa (NCT03679598)
- Testing
- Alvelestat (MPH966)
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Alabama at Birmingham
Copd, COPD Exacerbation
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
The goal of this pilot clinical trial is to compare telehealth and onsite supervised maintenance exercise program for adults with Chronic Lung Disease.
- Conditions
- Copd, COPD Exacerbation, COPD Bronchitis, Emphysema or COPD
- Trial name
- CLD (NCT06304207)
- Testing
- Onsite Maintenance Exercise Training, Telehealth Maintenance Exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- MGH Institute of Health Professions
COPD Asthma, Lung Neoplasm
Using Artificial Intelligence for the Detection of Respiratory Diseases Associated With Pollution
Generating a picture at the city level, through geospatial and temporal grouping a lung diseases associated or exacerbated by pollution (COPD, AB and neoplasm pulmonary or pleural) and correlating this data with pollution data.
- Conditions
- COPD Asthma, Lung Neoplasm, Emphysema
- Trial name
- SmartLungs (NCT06512142)
- Where
- Romania
- Volunteers
- 30,000 people
- Sponsor
- University of Medicine and Pharmacy "Victor Babes" Timisoara
COPD, Emphysema
Mechanistic Effects of Health Coaching to Reduce Chronic Obstructive Pulmonary Disease (COPD) Hospitalizations
The researchers are trying to explore the benefit of Health Coaching on patients with severe symptoms of COPD.
- Trial name
- NCT03837847
- Testing
- Health Coaching Calls, Control
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic